Remarkedly, the combination of MEK and AKT inhibitors obtained antitumor ability in certain KRAS-driven human cancers, in a cohort of patients with solid tumors receiving MEK1/2 inhibitor selumetinib and allosteric AKT inhibitors MK-2206, 3 of 13(23%) NSCLC patients and 1 of 2(50%) OVCA patients with KRAS mutation obtained PR, while there was no objective response in colorectal cancers with KRAS mutations [167]. Here, AKT1 is linked to colorectal cancer.